Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

3
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
3
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

5
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
5
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

4
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial.

Journal of the American Heart Association·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Left Atrial Reservoir Strain for Predicting Progression to End-Stage in Hypertrophic Cardiomyopathy.

European heart journal. Cardiovascular Imaging·2026
Same author

Distribution of peri-device leaks on transoesophageal echocardiography and cardiac computed tomography after WATCHMAN implantation: a multicentre core-lab analysis.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data.

Journal of the American Heart Association·2026

関連する実験動画

Updated: Jun 7, 2025

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.4K

血小管縮小のために推薦されたハイパルトロフィック心筋病患者におけるマヴァカムテン: 週128 VALOR- HCMの結果

Milind Y Desai1,2,3, Kathy Wolski2,3, Anjali Owens4

  • 1Hypertrophic Cardiomyopathy Center (M.Y.D., N.G.S.), Cleveland Clinic, OH.

Circulation
|November 18, 2024
PubMed
まとめ

閉塞性多動性心筋病 (HCM) の患者で128週間の間に渡って,マヴァカムテンはセプト縮小療法 (SRT) の必要性を有意に減少させた. ほとんどの患者は長期マバカメン治療を続け,症状の改善と阻害の減少を示した.

キーワード:
心筋病 縮症マバカメンセプトの縮小

さらに関連する動画

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.4K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.2K

関連する実験動画

Last Updated: Jun 7, 2025

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

3.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.4K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.2K

科学分野:

  • 心臓病科
  • 薬理学について
  • 臨床試験

背景:

  • 阻害性多動性心筋病 (HCM) は,症状のある患者の治療を必要とする重症疾患である.
  • 閉塞性HCMの患者にとって,セプト縮小療法 (SRT) は選択肢です.
  • Mavacamtenは,閉塞性HCMにおけるSRTの必要性を減らすために短期的な有効性を示しています.

研究 の 目的:

  • 閉塞性HCMの患者におけるマヴァカメンの長期的な効果を評価する.
  • 128週でSRTを避ける患者の割合を評価する.
  • 長期マバカメン治療の安全性と有効性を決定する.

主な方法:

  • 二重盲検,ランダム化,プラセボ対照試験 (VALOR- HCM) で,症状のある阻害性HCM患者でSRTを受ける資格があった.
  • 患者はマバカメンまたはプラセボを最大128週間投与し,エコーカルディオグラフィのパラメータに基づいて投与量を調整した.
  • 主要エンドポイントは,SRTを継続した患者数,または128週にガイドラインに適合した患者の割合でした.

主要な成果:

  • 128週目には,患者の15. 7%が複合エンドポイント (SRTを受けた,SRTを受ける資格があった,またはSRT状態は評価できない) を満たした.
  • 患者の80. 5%は,少なくとも1つのニューヨーク心臓協会のクラス改善を示し,左心室の流出経路の梯度が持続的に減少しました.
  • 13. 8% の患者で左心房エジェクション分数 < 50% が発生し,10. 2% の患者で新発性心房細動が発症した.

結論:

  • 閉塞性HCM患者の長期マバカメン治療は,128週後にSRTからの持続的な解放をもたらしました.
  • 患者の90%近くがマバカメタン治療を続け,持続的な臨床効果を示した.
  • マヴァカムテンは,重症症状の阻害性HCMの長期的な治療法として有望です.